secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0000950170-24-022053
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q4 revenue $28.6M (+78% YoY); LAL volume +98% YoY; guides FY2024 rev $128-135M
--------------------------------------------------------------------------------

- Q4 2023 revenue $28.6M, up 78% YoY, with 77 LDDs sold and 18,071 LALs (+98% YoY).
- Full year 2023 revenue $89.1M (+82% YoY); net loss $(48.6)M vs $(66.8)M in 2022.
- Q4 gross margin 62% vs 46% YoY; full year gross margin 60% vs 44%.
- FY2024 guidance: revenue $128M-$135M (44-52% growth); gross margin 65-67%; opex $125M-$128M.
- Cash and investments $127.2M at Dec 31; Q4 adjusted net loss $(4.8)M or $(0.13)/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024022053/0000950170-24-022053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017024022053/rxst-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-022053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer